Company Overview - Medpace Holdings, Inc. is a global, full-service clinical research organization (CRO) that serves biotech, pharmaceutical, and medical device companies, known for its trusted execution and consistent delivery of results [2] - The company generates revenue through various services including clinical trial management, regulatory and medical affairs, laboratory and imaging services, and pharmacovigilance and data management [2] Business Model and Growth - Medpace focuses on mid-sized biotech and pharma clients, allowing it to differentiate through precise execution and a fully integrated, in-house service platform that ensures seamless delivery across all trial stages [3] - The company has a track record of consistent double-digit growth and strong margins, supported by operational efficiency and streamlined processes that minimize delays [3] - Medpace's holistic approach accelerates trial timelines, supports regulatory approvals, and helps bring innovative treatments to patients more quickly [4] Investment Thesis - The combination of high-quality execution, an integrated service offering, and a recurring demand model positions Medpace as a resilient and high-quality growth platform within the CRO industry, making it an attractive investment opportunity [4] - The stock has appreciated approximately 73% since a previous bullish thesis was published, indicating strong market performance and consistent growth [5] Market Position - Medpace is not among the 30 most popular stocks among hedge funds, with 42 hedge fund portfolios holding MEDP at the end of the second quarter, unchanged from the previous quarter [6]